finanzen.net

MAUNA KEA TECHNOLOGIES Categorie -O- Aktie WKN: A1JCLA / ISIN: FR0010609263

1,63EUR
±0,00EUR
+0,25%
17.05.2019
1,72EUR
+0,06EUR
+3,61%
17.05.2019
KAUFEN
VERKAUFEN
mehr Daten anzeigen

MAUNA KEA TECHNOLOGIES Categorie -O- News

26.04.19
Mauna Kea Technologies SA (MKEA-FR): Progressing toward long-term strategic growth (EQS Group)
09.04.19
Mauna Kea Technologies SA (MKEA-FR): FY2018 results validate move to consignment sales (EQS Group)
25.02.19
Mauna Kea Technologies Receives 510(k) Clearance for the Cellvizio® Needle-Based AQ-Flex™ 19 Confocal Miniprobe™ Enabling Peripheral Lung Nodule Targeting and Imaging (Businesswire)
21.02.19
Mauna Kea Technologies Provides an Update on Its Commercial Partnership Agreement for Urological Applications (Businesswire)
18.01.19
Mauna Kea Technologies SA (MKEA-FR): Q4 performance generating momentum for 2019 (EQS Group)
22.10.18
Mauna Kea Technologies SA (MKEA-FR): Q3 sales indicate growing momentum: (EQS Group)
03.10.18
Mauna Kea Technologies Announces First Published Report of Live "Tele-Cellvizio®” Utilization In Vivo between Surgeons and Remote Pathologists (Businesswire)
26.09.18
Mauna Kea Technologies Announces the Publication in Surgical Endoscopy of Positive Results from Large U.S. Prospective Multi-Center Clinical Trial on Detection of Barrett’s Esophagus with Cellvizio® (Businesswire)
25.09.18
Mauna Kea Technologies SA (MKEA-FR): H1 results reflect continued focus on the US (EQS Group)
08.08.18
Elanix Biotechnologies AG (ELN-DE): Updates from webcast include financial outlook (EQS Group)
03.08.18
Mauna Kea Technologies SA (MKEA-FR): Q2 reveals consignment model is gaining traction (EQS Group)
25.07.18
Mauna Kea Technologies Reports Second Quarter and First Half 2018 Sales (Businesswire)
12.07.18
Mauna Kea Technologies SA (MKEA-FR): Optical biopsies for increased diagnostic accuracy (EQS Group)
20.06.18
Mauna Kea Technologies Announces Positive Results from Mayo Clinic Sponsored Prospective Multi-Center Trial in Lung Transplant Patients (Businesswire)
31.05.18
Mauna Kea Technologies Announces 20 Presentations Highlighting Cellvizio’s® Clinical Value in Evaluating Inflammatory Bowel Disease and Pancreatic Cysts at Digestive Disease Week® 2018 (Businesswire)
24.05.18
Mauna Kea Technologies Obtains First Ever FDA Clearance for Applications of Cellvizio® Confocal Laser Endomicroscopy in Neurosurgery (Businesswire)
13.04.18
Mauna Kea Technologies’ Cellvizio® Demonstrates Superior Identification of Patients at Risk for Esophageal Cancer Compared to Current Diagnostic Standard (Businesswire)
03.04.18
In Vivo Confocal Laser Endomicroscopy with Cellvizio®, a Technology Developed by Mauna Kea Technologies Allows the Discovery of a Previously Unknown Human Structure, the Interstitium (Businesswire)
15.03.18
Cellvizio® Obtains Positive Assessment from the Korean National Evidence-based healthcare Collaborating Agency (NECA) (Businesswire)
31.01.18
Mauna Kea Technologies Reports Fourth Quarter and Full Year 2017 Sales (Businesswire)
15.01.18
Mauna Kea Technologies Appoints Experienced Healthcare Executive, Molly O’Neill, to Board of Directors (Businesswire)
05.01.18
Mauna Kea Technologies Announces its 2018 Financial Calendar (Businesswire)
18.12.17
New FDA Clearance Validates In Vivo, Real-Time "Identification of Cellular and Vascular Organization and Architecture” Using Cellvizio® (Businesswire)
01.12.17
Mauna Kea Technologies Renews Its Equity Financing Facility to Support Its Development (Businesswire)
16.11.17
Mauna Kea Technologies Announces Reimbursement Coverage for Cellvizio® in Croatia (Businesswire)
30.10.17
Mauna Kea Technologies: New CONTACT Study Analysis Demonstrates Cellvizio’s Ability to Improve the Management of Patients with Pancreatic Cysts (Businesswire)
19.10.17
Mauna Kea Technologies Reports Third Quarter 2017 Sales (Businesswire)
17.10.17
Mauna Kea Technologies Appoints Olivier Regnard as Deputy CEO And Chief Financial Officer (Businesswire)
11.10.17
Mauna Kea Technologies: New Economic Model Shows Significant Cost Savings When Using Cellvizio® to Ascertain Diagnosis of Benign Pancreatic Cysts (Businesswire)
09.10.17
Mauna Kea Technologies: Cellvizio® Now CE Marked for Use During Robotic-Assisted Surgery (Businesswire)
06.10.17
Mauna Kea Technologies Renews Its Equity Financing Facility to Support Its Development (Businesswire)
20.09.17
Mauna Kea Technologies Reports First Half 2017 Financial Results (Businesswire)
05.09.17
Mauna Kea Technologies: Cook Medical Announces Commercial Launch of Cellvizio for Urology (Businesswire)
31.08.17
Mauna Kea Technologies Announces Strong Presence of Cellvizio at the OESO 14th World Conference (Businesswire)
07.08.17
Mauna Kea Technologies Receives Specific U.S. FDA 510(K) Clearance for Use of Cellvizio During Robotic-Assisted Surgery (Businesswire)
07.08.17
Mauna Kea Technologies Receives Specific U.S. FDA 510(k) Clearance for Use of Cellvizio During Robotic-Assisted Surgery (Businesswire)
02.08.17
Mauna Kea Technologies Announces Peer-Reviewed Publication of Key Multicenter Randomized Controlled Trial Demonstrating Improved Early Stomach Cancer Detection with Cellvizio (Businesswire)
25.07.17
Mauna Kea Technologies Reports First Half 2017 Sales (Businesswire)
19.06.17
Mauna Kea Technologies: New Publication Confirms Benefits of Using Cellvizio for Characterizing Upper Urinary Tract Cancer (Businesswire)
14.06.17
Mauna Kea Technologies to Present at the JMP Securities 2017 Life Sciences Conference (Businesswire)
Seite: 12

MAUNA KEA TECHNOLOGIES Categorie -O- News

MAUNA KEA TECHNOLOGIES Categorie -O- News: auf dieser Seite finden Sie alle MAUNA KEA TECHNOLOGIES Categorie -O- News und Nachrichten zur MAUNA KEA TECHNOLOGIES Categorie -O- Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch MAUNA KEA TECHNOLOGIES Categorie -O- News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um MAUNA KEA TECHNOLOGIES Categorie -O- News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.

MAUNA KEA TECHNOLOGIES Categorie -O- Peer Group News

Keine Nachrichten gefunden.

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Kolumnen
21:05 Uhr
Gold: Rettung in Sicht?
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Deutsche Bank AG514000
Daimler AG710000
Scout24 AGA12DM8
Wirecard AG747206
Amazon906866
Apple Inc.865985
TeslaA1CX3T
SAP SE716460
Allianz840400
BMW AG519000
BayerBAY001
Volkswagen (VW) AG Vz.766403
NEL ASAA0B733
E.ON SEENAG99
BASFBASF11